Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Deals

Shanghai Pharmaceuticals and Mindray Form Strategic Alliance for Medical Equipment and IVD Products

Fineline Cube Jul 19, 2023

Shanghai Pharmaceuticals (SHA: 601607, HKG: 2607), a leading pharmaceutical company in China, has announced a...

Company Deals

MindRank Ltd Secures Over $20 Million in Series A+ Funding to Advance AI Drug Development

Fineline Cube Jul 19, 2023

China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd has reportedly secured more than USD 20...

Company Deals

Zhejiang Dian Diagnostics Partners with Northeast Infectious Diseases Alliance to Enhance Surveillance

Fineline Cube Jul 19, 2023

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics specialist based in China, has...

Company Deals

Novartis Acquires DTx Pharma and Its FALCON Technology for Up to $1 Billion

Fineline Cube Jul 19, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced the acquisition of DTx Pharma Inc., a...

Company Deals

Allen Institute for Immunology Partners with Eli Lilly to Study Atopic Dermatitis and Rheumatoid Arthritis

Fineline Cube Jul 19, 2023

The US-based Allen Institute for Immunology has announced a strategic partnership with compatriot company Eli...

Company Deals

Pfizer and Flagship Pioneering Invest $100 Million in Drug Candidates Development

Fineline Cube Jul 19, 2023

Global pharmaceutical giant Pfizer (NYSE: PFE) and venture capital firm Flagship Pioneering have this week...

Company Drug

Qihan Biotech’s QN-019a Receives Clinical Clearance for Gene-Edited iPSC-Derived Cell Therapy in China

Fineline Cube Jul 19, 2023

Hangzhou Qihan Biotech Co., Ltd., a leading specialist in xenotransplantation based in China, has announced...

Company Deals

Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project

Fineline Cube Jul 19, 2023

This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN),...

Company Deals

Sumitomo Pharma to Invest $30 Million in China for New Product Development

Fineline Cube Jul 19, 2023

Japan-based Sumitomo Pharma (TYO: 4506), through its China unit, is planning a significant investment of...

Company Drug

Antengene Initiates Phase I ERASER Study for ATG-017 in Combination with Nivolumab

Fineline Cube Jul 19, 2023

China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced the first patient dosing in...

Company Drug

Sichuan Huiyu Pharmaceutical’s KRAS G12C Drug HYP-2090PTSA Accepted for NMPA Review

Fineline Cube Jul 19, 2023

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that the...

Company Deals Medical Device

Puncture Robotic Secures $13.9 Million in Series A+ Funding to Advance Medical Robotics

Fineline Cube Jul 19, 2023

Puncture Robotic, a Shanghai-based developer of medical robots, has reportedly raised RMB 100 million (USD...

Company Drug

Sanofi and AstraZeneca Receive FDA Approval for RSV Prevention Treatment Beyfortus

Fineline Cube Jul 18, 2023

France-based Sanofi (NASDAQ: SNY) has announced that it, along with AstraZeneca (AZ; NASDAQ: AZN), has...

Drug Policy / Regulatory

NMPA Releases 70th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jul 18, 2023

The National Medical Products Administration (NMPA) has released the 70th batch of reference drugs for...

Company Deals

Cutia Therapeutics’ CU-40101 Completes Phase I Clinical Trial for Androgenetic Alopecia

Fineline Cube Jul 18, 2023

Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced the completion of the...

Company Drug

Mabwell Bioscience’s 7MW3711 ADC for B7-H3 Gets Clinical Trial Approval in China

Fineline Cube Jul 18, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical...

Company Drug

Bayer’s Kerendia Officially Launched in China for Type 2 Diabetes-Related CKD

Fineline Cube Jul 18, 2023

German pharmaceutical giant Bayer’s (ETR: BAYN) Kerendia (finerenone), the first nonsteroidal, selective mineralocorticoid receptor (MR)...

Company Deals

Sensview Secures Tens of Millions in Series A+ Funding for X-Ray Detector Tech

Fineline Cube Jul 18, 2023

Sensview, a developer of solid-state imaging chips and detector module products based in Chengdu, has...

Company Deals

Nanjing Enrui Kainuo Biotechnology Secures Pre-Series A Funding for Cell Therapy Development

Fineline Cube Jul 18, 2023

Nanjing Enrui Kainuo Biotechnology Co., Ltd, a China-based cell therapy developer, has reportedly raised tens...

Company Drug

Shenzhen Salubris Pharmaceuticals Receives FDA Clearance for SAL0119 Clinical Trial

Fineline Cube Jul 18, 2023

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, has announced that it...

Posts pagination

1 … 554 555 556 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.